A detailed history of Simplex Trading, LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 7,984 shares of ARVN stock, worth $152,334. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,984
Holding current value
$152,334
% of portfolio
0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$23.66 - $32.73 $188,901 - $261,316
7,984 New
7,984 $196,000
Q4 2023

Feb 02, 2024

SELL
$14.19 - $42.33 $23,214 - $69,251
-1,636 Reduced 5.51%
28,070 $1.16 Million
Q3 2023

Nov 01, 2023

BUY
$19.64 - $28.21 $147,162 - $211,377
7,493 Added 33.73%
29,706 $583,000
Q2 2023

Aug 04, 2023

BUY
$21.73 - $31.43 $413,652 - $598,301
19,036 Added 599.18%
22,213 $551,000
Q1 2023

Apr 27, 2023

BUY
$26.15 - $37.26 $83,078 - $118,375
3,177 New
3,177 $86,000
Q3 2022

Nov 04, 2022

BUY
$41.87 - $57.99 $86,712 - $120,097
2,071 New
2,071 $92,000
Q1 2022

May 02, 2022

SELL
$60.27 - $81.57 $4,640 - $6,280
-77 Closed
0 $0
Q4 2021

Feb 23, 2022

SELL
$65.85 - $96.21 $360,331 - $526,461
-5,472 Reduced 98.61%
77 $6,000
Q3 2021

Oct 28, 2021

SELL
$73.2 - $107.87 $58,560 - $86,296
-800 Reduced 12.6%
5,549 $450,000
Q2 2021

Aug 12, 2021

BUY
$60.45 - $84.26 $202,567 - $282,355
3,351 Added 111.77%
6,349 $488,000
Q1 2021

Apr 26, 2021

SELL
$58.19 - $91.37 $981,839 - $1.54 Million
-16,873 Reduced 84.91%
2,998 $198,000
Q4 2020

Feb 02, 2021

BUY
$20.19 - $84.93 $320,314 - $1.35 Million
15,865 Added 396.03%
19,871 $1.69 Million
Q3 2020

Oct 14, 2020

BUY
$22.99 - $36.34 $92,097 - $145,578
4,006 New
4,006 $94,000
Q2 2020

Jul 13, 2020

SELL
$29.88 - $56.74 $27,609 - $52,427
-924 Closed
0 $0
Q1 2020

Apr 29, 2020

BUY
$33.0 - $54.5 $30,492 - $50,358
924 New
924 $37,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.